We performed a systematic review and meta-analysis of evidence for prevention of future cancers
following metabolic bariatric surgery (MBS). MBS was associated with significantly reduced overall
cancer incidence (RR 0.62, 95% CI 0.46–0.84, p < 0.002), obesity-related cancer (RR 0.59, 95% CI
0.39–0.90, p = 0.01) and cancer-associated mortality (RR 0.51, 95% CI 0.42–0.62, p < 0.00001). In
specific cancers, bariatric surgery was associated with reduction in future incidence of hepatocellular
carcinoma (RR 0.35, 95% CI 0.22–0.55, p < 0.00001), colorectal cancer (RR 0.63, CI 0.50–0.81, p =
0.0002), pancreatic cancer (RR 0.52, 95% CI 0.29–0.93, p = 0.03) and gallbladder cancer (RR 0.41,
95% CI 0.18–0.96, p = 0.04), as well as female specific cancers, including breast cancer (RR 0.56,
95% CI 0.44–0.71, p < 0.00001), endometrial cancer (RR 0.38, 95% CI 0.26–0.55, p < 0.00001) and
ovarian cancer (RR 0.45, 95% CI 0.31–0.64, p < 0.0001). Obesity-associated carcinogenesis is
related to metabolic syndrome; visceral adipose dysfunction; aromatase activity and detrimental
cytokine, adipokine and exosomal miRNA release. MBS improves metabolic syndrome, results in
long-term weight loss in morbidly obese patients, and may decrease future overall cancer incidence
and mortality.
We performed a systematic review and meta-analysis of evidence for prevention of future cancers
following metabolic bariatric surgery (MBS). MBS was associated with significantly reduced overall
cancer incidence (RR 0.62, 95% CI 0.46–0.84, p < 0.002), obesity-related cancer (RR 0.59, 95% CI
0.39–0.90, p = 0.01) and cancer-associated mortality (RR 0.51, 95% CI 0.42–0.62, p < 0.00001). In
specific cancers, bariatric surgery was associated with reduction in future incidence of hepatocellular
carcinoma (RR 0.35, 95% CI 0.22–0.55, p < 0.00001), colorectal cancer (RR 0.63, CI 0.50–0.81, p =
0.0002), pancreatic cancer (RR 0.52, 95% CI 0.29–0.93, p = 0.03) and gallbladder cancer (RR 0.41,
95% CI 0.18–0.96, p = 0.04), as well as female specific cancers, including breast cancer (RR 0.56,
95% CI 0.44–0.71, p < 0.00001), endometrial cancer (RR 0.38, 95% CI 0.26–0.55, p < 0.00001) and
ovarian cancer (RR 0.45, 95% CI 0.31–0.64, p < 0.0001). Obesity-associated carcinogenesis is
related to metabolic syndrome; visceral adipose dysfunction; aromatase activity and detrimental
cytokine, adipokine and exosomal miRNA release. MBS improves metabolic syndrome, results in
long-term weight loss in morbidly obese patients, and may decrease future overall cancer incidence
and mortality.